Clinical trial
Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type
NCT00297362 is registered in ClinicalTrials.gov with Janssen Cilag Pharmaceutica S.A.C.I., Greece as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type
- Lead sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 30, 2004
- Completion date
- October 31, 2005
- Enrollment
- 344 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.